These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 30642877)

  • 1. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.
    Estrada CC; Maldonado A; Mallipattu SK
    J Am Soc Nephrol; 2019 Feb; 30(2):187-200. PubMed ID: 30642877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
    Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
    Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
    Barr MP; Gray SG; Gately K; Hams E; Fallon PG; Davies AM; Richard DJ; Pidgeon GP; O'Byrne KJ
    Mol Cancer; 2015 Feb; 14():45. PubMed ID: 25889301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aflibercept: a novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors.
    Sharma T; Dhingra R; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
    Mini Rev Med Chem; 2013 Apr; 13(4):530-40. PubMed ID: 23317499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-VEGF Molecules for the Management of Diabetic Macular Edema.
    Bandello F; Cicinelli MV; Parodi MB
    Curr Pharm Des; 2015; 21(32):4731-7. PubMed ID: 26350530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes.
    MacDonald DA; Martin J; Muthusamy KK; Luo JK; Pyles E; Rafique A; Huang T; Potocky T; Liu Y; Cao J; Bono F; Delesque N; Savi P; Francis J; Amirkhosravi A; Meyer T; Romano C; Glinka M; Yancopoulos GD; Stahl N; Wiegand SJ; Papadopoulos N
    Angiogenesis; 2016 Jul; 19(3):389-406. PubMed ID: 27234973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family.
    Zachary I; Gliki G
    Cardiovasc Res; 2001 Feb; 49(3):568-81. PubMed ID: 11166270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
    Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
    Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
    Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
    BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
    Jampol LM; Glassman AR; Liu D; Aiello LP; Bressler NM; Duh EJ; Quaggin S; Wells JA; Wykoff CC;
    Ophthalmology; 2018 Jul; 125(7):1054-1063. PubMed ID: 29525602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal thrombotic microangiopathy during nintedanib treatment for idiopathic pulmonary fibrosis
.
    Inoue D; Nishi H; Honda K; Ishii T; Abe H; Sato M; Nangaku M
    Clin Nephrol; 2020 Jan; 93(1):47-50. PubMed ID: 31699213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aflibercept a new target therapy in cancer treatment: a review.
    Ricci V; Ronzoni M; Fabozzi T
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):569-76. PubMed ID: 26224565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.